Chris Shanahan

Chris is a principal on the investment team at DFJ Growth. His areas of focus include companies building at the intersection of hardware and software—including defensetech, autonomy, energy, robotics, & smart systems—as well as companies innovating in lifetech. Chris has been involved with the firm’s investments in Cellanome, Cellares, Commonwealth Fusion, Glowforge, Hidden Level, Neocis, Neuralink, NotCo, Paradigm Health, SpaceX, Vannevar Labs, X, and xAI.

Chris served as a DFJ Growth Fellow embedded at portfolio company Neuralink working on special projects across a range of functional areas in 2022.

Prior to joining DFJ Growth in February 2018, Chris was an analyst at Greenhill & Co., where he focused on mergers and acquisitions across a range of industries. He previously held roles in research and development engineering at Boston’s Scientific’s neuromodulation division and Johnson & Johnson’s Acclarent division.

Chris has a bachelor of science with honors in biomedical engineering from Cal Poly.